Interplay of On-demand Trials for Hereditary Angioedema Attacks and Treatment Guidelines
Efficacy and Safety of Sebetralstat for On-demand Treatment of Hereditary Angioedema in Pooled Analysis of Placebo-controlled Clinical Trials
Effectiveness of Sebetralstat for the On-demand Treatment of Laryngeal Hereditary Angioedema Attacks: Interim Analysis from KONFIDENT-S
On-demand Treatment Of Hereditary Angioedema Attacks With Sebetralstat In Adolescents: Pooled Analysis From KONFIDENT And KONFIDENT-S
Safety and Effectiveness of Sebetralstat in Patients with Hereditary Angioedema Receiving Long-term Prophylaxis: Interim Analysis from the KONFIDENT-S Open-label Study
Sebetralstat for Treatment of Hereditary Angioedema Attacks in Patients Receiving Berotralstat: Interim Analysis from the KONFIDENT-S Open-label Study
Efficacy and Safety of Sebetralstat for On-demand Treatment of Hereditary Angioedema in Pooled Analysis of Placebo-controlled Clinical Trials
Patrick Yong, Jonathan Bernstein, Danny Cohn, Henriette Farkas, William Lumry, Marc Riedl, Andrea Zanichelli, James Hao, Michael Smith, Christopher Yea, Paul Audhya, Emel Aygoren-Pursun, Sinisa Savic, Sorena Kiani-Alikhan Presented at British Society for Immunology Clinical Immunology Professional Network (BSI-CIPN) Conference; December 9-10, 2024; Birmingham, United Kingdom
Correlation of Time to Treatment with Attack Duration in the Sebetralstat KONFIDENT Phase 3 Trial
Indirect Treatment Comparison of Oral Sebetralstat and Intravenous rhC1-INH as On-demand Treatments for Hereditary Angioedema
On-demand Treatment of Laryngeal Hereditary Angioedema Attacks with Sebetralstat: Pooled Analysis from KONFIDENT and KONFIDENT-S
Substantial Reduction of Hereditary Angioedema Attack Symptom Burden in the Sebetralstat Phase 3 KONFIDENT Trial
Impact of Oral Sebetralstat on Hereditary Angioedema Attack-associated Anxiety: Analysis From the Phase 3 KONFIDENT Trial
KONFIDENT Trial of Oral Sebetralstat for Treatment of Hereditary Angioedema Attacks: Analysis of the European and US Patient Populations
Advent of Oral Medications for the Treatment of Hereditary Angioedema
KONFIDENT-S Interim Analysis: Sebetralstat for Hereditary Angioedema Attacks Including Laryngeal
Pooled Sebetralstat Placebo-controlled Efficacy for On-demand Treatment of Hereditary Angioedema
Pooled Sebetralstat Placebo-controlled Safety for On-demand Treatment of Hereditary Angioedema
Oral Sebetralstat for On-demand Treatment of Hereditary Angioedema Attacks
Sebetralstat as Oral On-demand Treatment for Hereditary Angioedema: Interim Analysis of the Open-label KONFIDENT-S Trial
Sebetralstat for On-demand Treatment of Hereditary Angioedema Attacks: US Subgroup Analysis from the Double-blind, Placebo-controlled Phase 3 KONFIDENT Trial
Sebetralstat: A Rapidly Acting Plasma Kallikrein Inhibitor for the On-demand Treatment of Hereditary Angioedema
KONFIDENT Phase 3 Trial Global Expansion: Sebetralstat Pharmacokinetics and Pharmacodynamics in Japanese and Chinese Adults
Evaluation of Patient-reported Outcome Measures for On-demand Treatment of Hereditary Angioedema Attacks and Design of KONFIDENT, a Phase 3 trial of Sebetralstat
Results From a Randomized, Double-Blind, Placebo-Controlled, Phase 1 Trial Evaluating Sebetralstat Pharmacokinetics, Pharmacodynamics, and Safety/Tolerability in Healthy Japanese, Chinese, and White Adults
Short-term Prophylaxis with Sebetralstat, an Investigational On-demand Treatment for Hereditary Angioedema, in KONFIDENT-S
Sebetralstat Effectiveness in the Treatment of Hereditary Angioedema Attacks Rated Mild or Moderate at Baseline in the Phase 2 Trial
Rationale for the Short-term Prophylaxis Regimen with Sebetralstat in KONFIDENT-S
Comparative Bioavailability of Sebetralstat Following Administration of Orally Disintegrating Tablets and Film-Coated Tablets in Healthy Volunteers
Treatment with Sebetralstat Reduces the Cumulative Symptom Severity of Hereditary Angioedema Attacks in a Phase 2 Trial
An Investigational Oral Plasma Kallikrein Inhibitor for On-demand Treatment of Hereditary Angioedema: A Two-part, Randomized, Double-blind, Placebo-controlled, Crossover Phase 2 Trial
Efficacy of the Oral Plasma Kallikrein Inhibitor Sebetralstat (KVD900) by Attack Location in a Phase 2 Clinical Trial in Patients with Hereditary Angioedema
Pharmacokinetic, Pharmacodynamic, and Safety Profile in Healthy Japanese and White Adults: Results from Phase 1, Randomized, Double-blind, Placebo-controlled Trial
Sebetralstat (KVD900): A Potent and Selective Small Molecule Plasma Kallikrein Inhibitor Featuring a Novel P1 Group as a Potential On-demand Treatment for Hereditary Angioedema
Patient Perspectives on an Optimal Outcome Measure to Assess Efficacy in the Acute Treatment of Hereditary Angioedema Attacks
Pharmacological Suppression of the Kallikrein Kinin System with KVD900: An Orally Available Plasma Kallikrein Inhibitor for the On-demand Treatment of Hereditary Angioedema
Absorption, Metabolism and Excretion of Sebetralstat (KVD900) Following a Single Oral Dose in Healthy Male Participants
Population Pharmacokinetic Analysis of Sebetralstat (KVD900) in Healthy Volunteers and Patients with Hereditary Angioedema Predicts Similar Exposure in Adolescent Patients
KVD900, An Oral On-demand Treatment for Hereditary Angioedema; Phase 1 Study Results
Agreement Between Improvements in Patient Global Assessment of Change and Other Measures of Improvement and Attack Resolution Observed in a Phase 2 Trial with Sebetralstat (KVD900) in Patients with Hereditary Angioedema
Agreement of Patient Global Assessment of Change With Attack Resolution or Use of Rescue Medication in Patients with Hereditary Angioedema
